Patents Represented by Attorney, Agent or Law Firm David M. Gryte
-
Patent number: 8030500Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: GrantFiled: November 13, 2009Date of Patent: October 4, 2011Assignee: AstraZeneca ABInventors: Jörg Holenz, Sofia Karlström, Karin Kolmodin, Johan Lindström, Laszlo Rakos, Didier Rotticci, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg
-
Patent number: 7767708Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.Type: GrantFiled: November 1, 1999Date of Patent: August 3, 2010Assignee: Schering-Plough Animal Health Corp.Inventors: Shih Chung, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
-
Patent number: 7670591Abstract: The present invention relates to novel heteroaryl substituted benzoxazole derivatives and therapeutic uses for such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzoxazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: GrantFiled: June 14, 2007Date of Patent: March 2, 2010Assignee: AstraZeneca ABInventors: Jonas Malmstrom, David Pyring, Can Slivo, Daniel Sohn, Britt-Marie Swahn, David Wensbo
-
Patent number: 7629356Abstract: This invention relates to substituted pyrrolo[3,4-b]pyridinamines having the structural formula IA below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: GrantFiled: May 15, 2008Date of Patent: December 8, 2009Assignees: AstraZeneca AB, Astex TherapeuticsInventors: Gianni Chessari, Miles Stuart Congreve, Jörg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
-
Patent number: 7482020Abstract: A process for making an adjuvanted vaccine comprising host albumin. The process comprises mixing host serum or host serum with an antigen, and then mixing the resulting mixture with an adjuvant.Type: GrantFiled: September 2, 2003Date of Patent: January 27, 2009Inventors: Kristina J. Hennessy, Karen K. Brown, Jennifer K. Lane, Sandra L. Trump
-
Patent number: 6617324Abstract: A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.Type: GrantFiled: April 2, 2002Date of Patent: September 9, 2003Assignee: G. D. Searle & CompanyInventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xi, Ish K. Khanna, Yi Yu
-
Patent number: 6583299Abstract: A family of molecules is disclosed that inhibit matrix metalloprotease (MMP) activity, and particularly inhibit the activity of one or more of MMP-2, MMP-9, or MMP-13, while generally exhibiting little activity against MMP-1. A contemplated compound also exhibits little inhibition of the production of TNF. A contemplated compound is an &agr;-amino-&bgr;-sulfonyl carbocyclo, heterocyclo, aryl, or heteroaryl hydroxamic acid. Also disclosed are processes for preparing a contemplated compound and for treating a mammal having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: May 16, 2000Date of Patent: June 24, 2003Assignee: G.D. Searle & Co.Inventors: Susan L Hockerman, Daniel P. Becker, Louis J Bedell, Gary A DeCrescenzo, John N Freskos, Daniel P Getman, Robert M Heintz, Madeleine H Li, Brent V Mischke, Clara I Villamil, Thomas E Barta
-
Patent number: 6509361Abstract: The present invention contemplates 1,5-diaryl-substituted pyrazole compounds that, inter alia, inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase- or TNF-mediated disease.Type: GrantFiled: February 12, 2001Date of Patent: January 21, 2003Assignee: Pharmacia CorporationInventors: Richard M. Weier, Joyce Z. Crich, Xiang Dong Xu, Paul W. Collins
-
Patent number: 6503930Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I wherein Q, R1, R2, R3 and R4 are as described in the specification.Type: GrantFiled: March 31, 2000Date of Patent: January 7, 2003Assignee: G.D. Searle & CompanyInventors: Gunnar J. Hanson, Shuyuan Liao
-
Patent number: 6492367Abstract: A sulfamato hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a process for preparing the same, intermediate compounds useful in those syntheses, and a treatment process that comprises administering a contemplated sulfamato hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: February 26, 2002Date of Patent: December 10, 2002Assignee: G. D. Searle & CompanyInventors: Gary A DeCrescenzo, Joseph G Rico, Terri Boehm, Jeffery N Carroll, Darren J Kassab, Deborah A Mischke, Shashidhar Rao
-
Patent number: 6482955Abstract: This invention relates to a novel process of preparing selected 5-substituted pyrazoles useful as p38 kinase and COX-2 inhibitors.Type: GrantFiled: August 6, 2001Date of Patent: November 19, 2002Assignee: Pharmacia CorporationInventors: Matthew J. Graneto, Susan J. Hartmann, Suzanne Metz, John J. Talley, Michael L. Vazquez, David Brown, Richard M. Weier, Michael A. Stealey, Xiangdong Xu